Relmada Secures Long Runway with $244M Financing, Advances NDV-01 to Phase 3, Resolves Going Concern

summarizeSummary

Relmada Therapeutics reported Q1 2026 results, confirming a strong cash position from recent financings that resolved its going concern status, alongside positive Phase 2 data and FDA alignment for Phase 3 trials for its lead bladder cancer drug, NDV-01.

check_boxKey Events · Earnings and Guidance · RLMD

• Going Concern Status Resolved

  Management now believes existing cash and investments provide a runway for at least 12 months, resolving the previously disclosed 'going concern' doubt.

• Significant Capital Raise Confirmed

  The company confirmed net proceeds of approximately $150 million from a private placement in March 2026 and $94 million from an underwritten offering in November 2025, totaling $244 million.

• Positive NDV-01 Phase 2 Data

  Relmada reported positive 12-month safety and efficacy data for its NDV-01 program in high-risk non-muscle invasive bladder cancer (NMIBC), showing a 76% complete response rate at 12 months with no new safety signals.

• FDA Alignment for NDV-01 Phase 3 Trials

  The company secured FDA alignment for two planned Phase 3 pivotal programs for NDV-01 in NMIBC, with trials expected to initiate mid-2026.

auto_awesomeAnalysis · RLMD · Life Sciences

This quarterly report confirms Relmada's significantly improved financial position, driven by recent capital raises totaling $244 million. This funding has resolved the company's 'going concern' status, providing a cash runway for at least 12 months. Operationally, the company reported positive 12-month Phase 2 data for NDV-01 in bladder cancer and secured FDA alignment for two Phase 3 trials, expected to start mid-2026. These developments are critical for a clinical-stage biotech, de-risking its operations and advancing its pipeline towards commercialization.